Abstract Details

Title A Population Based Assessment of Polyneuropathy and Associated Disability

Topic Peripheral Nerve

Presentation(s) S58 - (-)

Poster/Presentation
Number 003

Objective

Background Population based studies on polyneuropathy epidemiology are lacking. Every three years in Olmsted County, 96% of the residents are seen by a healthcare provider and their medical records are available within the Rochester Epidemiology Project (REP), whose census exceeds the U.S. Census estimate (138,420 in 2008). Nearly complete medical record availability for the entire population, access to approximately 100 local neurologists, and similarity to the U.S. population apart from greater educational background provides an ideal setting for our objective.

Design/Methods ICD-9 codes were used to define the polyneuropathy epidemiology from 2006-2010. Information on medications, diabetes, foot ulcers, amputations, and symptom questionnaires were obtained for preliminary assessment of the extent (disability) of polyneuropathy in this cohort.

Results The incidence of polyneuropathy was 247 per 100,000 person-years. Prevalence rose with age and peaked in the 8th decade for both males (11.2%) and females (7.9%). Numbers of polyneuropathy cases by subtype were: 1,450 idiopathic (50.1%), 1,104 diabetic (38.1%), 135 inflammatory (4.7%), 89 hereditary (3.1%), 84 toxic (2.9%), and 35 other (1.2%). Gabapentin or pregabalin were prescribed to 38.1% of patients. Foot ulcers and amputations occurred in 20.3% and 2.9% of all patients, respectively. Questionnaire responses were available on 73% of patients and documented many relevant symptoms, including pain (26%), difficulty or inability to climb stairs (54.5%), and use of assistive devices (27%). Neurological examination sheets demonstrated the impairments for patients seen by neurology with 44% undergoing EMG. Further detailed chart review is underway.

Conclusions Polyneuropathy is common in the general population especially among older individuals. Significant disability is associated with polyneuropathy and with an aging U.S. population and increasing rates of diabetes the burden of polyneuropathy is predicted to increase. This cohort provides a unique resource for detailed understanding of polyneuropathies.

Authors/Disclosures
E. M. Hoffman, DO, PhD (Mayo Clinic, Neurology) PRESENTER	Dr. Hoffman has nothing to disclose.
Nathan P. Staff, MD, PhD, FAAN (Mayo Clinic)	Dr. Staff has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stem Cell Research & Therapy. Dr. Staff has received research support from National Institutes of Health.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Christopher J. Klein, MD, FAAN (Mayo Clinic)	Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sangamo Therapeutics . Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma.
	No disclosure on file

��ɫ��

��ɫ��